Reason why melanoma therapy Zelboraf failed to be registered for insurance benefit
A Roche Korea’s metastatic melanoma treatment ‘Zelboraf(vemurafenib)’ is a drug which still has not been registered in the drug insurance benefit list for more than 4 years after acquiring commercialization approval in Korea. The company made two attempts through the general registration process ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
